Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Xylocor Therapeutics Inc.
Headquarters: Wayne, PA, United States of America
Website: https://xylocor.com/
Year Founded: 2013
Status: Private
BioCentury | Jan 11, 2025
Finance
Pre-JPM venture bonanza
Fourteen companies announce series A rounds ahead of conference, six with over $100 million
BioCentury | Jul 16, 2024
Deals
Deals report: Ipsen gets second ADC; Context buys MSLN
Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships
BioCentury | Jan 19, 2022
Management Tracks
Interim no more: Zhang assumes Overland’s CEO post; Maraganore, Ho join as advisers
Plus: Merck KGaA strategy, R&D execs; and updates from CureVac, Exo, Krystal and more
BioCentury | Mar 24, 2021
Deals
March 23 Quick Takes: Moulder’s Zenas launches; plus PhoreMost, 1910 Genetics, XyloCor and Catalent
Lonnie Moulder’s cross-border biotech Zenas BioPharma launched Tuesday to develop immune-based therapies. Moulder, the co-founder and CEO of Tesaro Inc., is executive chairman and interim CEO
BioCentury | Aug 12, 2019
Company News
Management tracks: Bailey leaving GSK; plus HHS drug pricing adviser to depart and more
BioCentury | Jul 19, 2019
Regulation
A half step forward for heart failure as FDA guidance leaves key question unanswered
FDA will need to nail down details in its heart failure guidance to really boost investment
BioCentury | Dec 7, 2018
Financial News
Angina gene therapy company XyloCor raises $17M series A round
BioCentury | Dec 6, 2018
Financial News
Angina gene therapy company XyloCor raises $17M series A round
Items per page:
1 - 8 of 8